Posted on July 11, 2009 by Sitemaster
In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, monotherapy, pprophylaxis, tamoxifen | 1 Comment »
Posted on July 10, 2009 by Sitemaster
Better understanding of how different men respond to the uncertainty and quality of life issues associated with active surveillance as a method to manage low- and intermediate-risk prostate cancer has the potential to enhance the delivery of care for such patients.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, quality of life, uncertainty | 2 Comments »
Posted on July 10, 2009 by Sitemaster
As we have suggested before in these reports, the question of whether mass, population-based screening for certain cancers (including prostate cancer) is really the best strategy for prevention of risk from the disease itself is a complex one.
Filed under: Diagnosis, Management, Risk | Tagged: breast, cancer, risk, screening | 4 Comments »
Posted on July 9, 2009 by Sitemaster
Today’s news reports address such items as: Finasteride in the prevention of prostate cancer Nitric oxide treatment in men with a rising PSA after first-line therapy Decreased use of LHRH agonist therapy since 2003
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: finasteride, LHRH agonist, nitric oxide, Prevention, risk | Leave a Comment »
Posted on July 8, 2009 by Sitemaster
Today’s prostate cancer news reports cover items on: Assessment of quality of life after radical prostatectomy Permanent seed brachytherapy in treatment of localized disease Cryotherapy in treatment of patients with Gleason 8-10 localized disease Actonel and/or estradiol in prevention of SREs
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Actonel, brachytherapy, cryotherapy, estradiol, Gleason score, outcome, permanent, quality of life, risedronate, seed, survey | Leave a Comment »
Posted on July 8, 2009 by Sitemaster
A Swiss prostate cancer research trust (Stiftung Prostrata) paired with ad agency Jung von Matt/Limatt to come up an eye-catching series of print advertisements encouraging men to get a PSA test.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA test, risk | Leave a Comment »
Posted on July 8, 2009 by Sitemaster
An analysis by Roehrborn et al. has come up with a mean, per-patient cost of just over $13,000 for managing the care of a newly diagnosed prostate cancer patient for the first year after his diagnosis in the USA, inclusive of actual treatment costs.
Filed under: Management, Treatment | Tagged: cost, first year, Treatment | Leave a Comment »
Posted on July 8, 2009 by Sitemaster
According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, Casodex, generic | Comments Off
Posted on July 8, 2009 by Sitemaster
Some (maybe many) readers of this column are not going to like an article on the front page of the New York Times today.
Filed under: Management, Treatment | Tagged: economics, reform | 6 Comments »
Posted on July 7, 2009 by Sitemaster
Amgen, the developer of denosumab (also known as RANK-L) has released data today from a head-to-head trial of their drug vs. zoledronate (Zometa) in the management of patients with advanced breast cancer and bone metastases.
Filed under: Drugs in development | Tagged: denosumab, skeletal-related events, SREs, zoledronate | Leave a Comment »
Posted on July 7, 2009 by Sitemaster
GTx has announced a second Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone (LH) inhibitor (not an LHRH agonist or an LHRH antagonist), for first-line treatment of advanced prostate cancer.
Filed under: Drugs in development, Uncategorized | Tagged: GTx, GTx-758, inhibitor, LH, luteinizing hormone | Leave a Comment »
Posted on July 7, 2009 by Sitemaster
In today’s news reports we address new data on: The possible association between PSA levels and SNPs Patient age at diagnosis and prostate cancer outcomes Revalidation of the Stephenson nomogram for outcomes after salvage radiation therapy Failure to follow best practices for radiation of bony metastases
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: age, best practices, Diagnosis, external beam radiation, nomogram, PSA, salvage, single nucleotide polymorphism, SNP | Leave a Comment »
Posted on July 6, 2009 by Sitemaster
We are pleased to announce that Mark Emberton, MD, FRCS has accepted an invitation to join the Scientific Advisory Board of The “New” Prostate Cancer InfoLink.
Filed under: Uncategorized | Comments Off
Posted on July 5, 2009 by Sitemaster
For many years now, the prostate cancer “screening” issue has been framed by two opposing and “extreme” points of view.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: risk, screening | 12 Comments »
Posted on July 4, 2009 by Sitemaster
The following commentary reports with greater accuracy and in more detail on the same article, dealing with the same series of 172 HIFU patients, as was previously discussed on this web site on July 2 this year. The original report was based solely on the abstract of the article.
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound | 5 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
